The Novel RSV Vaccine: Part 2

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 2 of a two-part series examining new research on the proposed RSV vaccine. The GameChangerRSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in pregnant patients may help newborns.  Show Segments00:00 - Introductions02:57 - Recap From Part 106:45 - Looking at the MATISSE Study14:17 - The GameChanger: MATISSE Results22:27 - Connecting to Practice: Barriers to Applying 31:05 - Closing Remarks  HostGeoff Wall, PharmD, BCPS, FCCP, BCGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health GuestJake Galdo, PharmD, MBA, BCPS, BCGP Managing Network Facilitator, CPESN Health Equity CEO, Seguridad ReferenceKampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.Pharmacist Members, REDEEM YOUR CPE HERE!Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss the MATISSE study in relation to RSV vaccines2. Describe barriers to applying the information in this study to general populations 0.05 CEU/0.5 Hr UAN: 0107-0000-23-193-H06-P Initial release date: 05/08/2023 Expiration date: 05/08/2024 Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram